Merck discontinues Phase 3 KeyVibe-010 trial of coformulation of Vibostolimab and Pembrolizumab

Data showed that the primary endpoint of recurrence-free survival (RFS) met the pre-specified futility criteria

Novartis to acquire Mariana Oncology for upfront US$ 1 billion

Acquisition encompasses a portfolio of RLT programs across a range of solid tumor indications

Merck announces positive data for investigational, 21-Valent pneumococcal conjugate vaccine

Late-breaker Phase 3 STRIDE-10 trial presented as an oral presentation at European Society of Clinical Microbiology and Infectious Diseases

Novartis and Medicines for Malaria Venture announce positive efficacy and safety data

The CALINA study tested a new ratio and dose of Coartem to account for metabolic differences in babies under 5 kg

PharmaLytica 2024 to draw 200+ exhibitors

10th edition of the event is scheduled to be held during May 30-June 1 at Hitex, Hyderabad

Positive data for Roche multiple sclerosis injection

US FDA and EMA accepted filings based on the data from OCARINA II, with EU approval anticipated mid-2024 and U.S. approval anticipated September 2024

Suven Life Sciences to present phase-2 results on Samelisant at AAN 2024

Global Phase-3 study initiation expected in the second half of 2024

Merck India appoints Dhananjay Singh as MD Merck Life Science in India

Pfizer announces positive results from Phase 3 Study of Abrysvo

ABRYSVO met its trial primary endpoints in adults aged 18 to 59 with an increased respiratory syncytial virus (RSV) disease risk.

Piramal Pharma forays into men's grooming market in India with the launch of BOHEM